Biological Therapeutic Products

Conferences & Courses
Antibodies for Cancer Therapy Antibodies for Cancer Therapy
May 5-6, 2014 | Boston, MA
The field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market.

Phage and Yeast Display of Antibodies and Recombinant Proteins Phage and Yeast Display of Antibodies and Recombinant Proteins
May 5-6, 2014 | Boston, MA
Directed evolution of molecules is fundamental to generating a wide variety of constructs and helping to drive the biologics market which is valued at more than $120 Billion.

Difficult to Express Proteins Difficult to Express Proteins
May 5-6, 2014 | Boston, MA
Membrane proteins, ion channels, toxic or insoluble proteins, low abundance protein complexes, vaccines and other “finicky” proteins often are the best choices for therapeutics, yet their successful expression is a minefield of failures and challenges.




Life Science Media Library
Antibody-Drug Conjugates-Engineering for Success Antibody-Drug Conjugates-Engineering for Success
January 22, 2013 |
This course provides a detailed look into the discovery, characterization, and manufacturing of Antibody-Drug Conjugates, with a particular focus on safety issues. Featured is an in-depth and extensive case study from Genentech about their use of antibody-drug conjugates in a robust bio-oncology program, including a focus on risk mitigation and risk minimization strategies. This talk is followed by a presentation about Sutro Biopharma’s Open Cell Free Synthesis (OCFS) technology for screening, selecting and formulating ADCs. Finally, an excellent overview of the infrastructure required to produce these molecules is presented by Lonza. All three presentations are filled with first-hand insights and practical approaches to successfully developing these potent biologics.
Navigating the Regulatory Hierarchy of Immunogenicity Navigating the Regulatory Hierarchy of Immunogenicity
October 9, 2012 |
Immunogenicity Summit 2012, led by Dr Amy Rosenberg, Director of the Division of Therapeutic Proteins at CDER and Paul Chamberlain from the NDA Advisory Board, a well recognized and experienced expert in presenting immunogenicity risk assessments to European and North American regulatory agencies. This product covers product quality aspects and clinical consequences and the immunogenicity risk assessment process, and provides real examples demonstrating the application of principles and an interactive case study.
Engineering of Bispecific Antibodies Engineering of Bispecific Antibodies
April 29, 2012 |
This DVD provides a great overview of affinity tags along with an excellent case study of developing tandem affinity purification (TAP)-mass spectrometry approaches to protein purification. Bill Gillette (from SAIC-NCI Frederick) has personally purified over 800 unique proteins, and generously shares his extensive knowledge and experience including interactive discussions with the course participants. Alexey Veraksa(from UMass Boston) discusses the advantages and pitfalls associated with the use of the original TAP tag and the more recently developed GS-TAP tag, and shares his group’s new data on developing even more efficient ways to isolate and analyze protein complexes.




Publications, Reports, & Whitepapers
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.